Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 2 (2005), Issue 6 (June)

1. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
   J Cell Physiol, 204(2): 463-9. [Abstract] [Full-text]
2. Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer.
   Onkologie, 28(6): 318-22. [Abstract] [Full-text]
3. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
   Eur J Cancer, 41(9): 1349-61. [Abstract] [Full-text]
4. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
   J Cancer Res Clin Oncol, 131(7): 420-8. [Abstract] [Full-text]
5. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
   Pathol Int, 55(6): 318-23. [Abstract] [Full-text]
6. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels.
   Pharm Res, 22(6): 915-22. [Abstract] [Full-text]
7. Relationship between the expression of various markers and prognostic factors in breast cancer.
   Acta Histochem, 107(2): 87-93. [Abstract] [Full-text]
8. A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
   Expert Opin Biol Ther, 5(6): 853-66. [Abstract] [Full-text]
9. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
   Clin Cancer Res, 11(12): 4561-70. [Abstract] [Full-text]
10. The role of taxanes in the treatment of breast cancer.
    Expert Opin Pharmacother, 6(7): 1073-94. [Abstract] [Full-text]
11. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Int J Cancer, 116(3): 359-67. [Abstract] [Full-text]
12. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
    Eur J Cancer, 41(10): 1467-73. [Abstract] [Full-text]
13. 'At the point at which you can do something about it, then it becomes more relevant': informed consent in the pharmacogenetic clinic.
    Soc Sci Med, 61(6): 1201-10. [Abstract] [Full-text]
14. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Breast Cancer Res, 7(4): R436-43. [Abstract] [Full-text]
15. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
    Oncogene, 24(28): 4540-8. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.